National Innovation Award

LabTurbo Biotech Honored with National Innovation Award

December 1st, LabTurbo also won the Pharmaceutical Science and Technology Research and Development Award given by the Ministry of Health and Welfare, and the Ministry of Economic Affairs and will be awarded on December 15th.
Eric Dai (fifth from left), the general manager of LabTurbo Biotech, the research team of Dr. Xu Huiling (forth from left) of Institute of Preventive Medicine, Cai Shihong (third from left), director of Tri-Service General Hospital and his group of doctors pose with the National Innovation Award mutually.

Eric Dai, the CEO of LabTurbo Biotech expressed his thanks, in particular, to researchers from Institute of Preventive Medicine of National Defense Medical Center for their outstanding work and assistance with LabTurbo’s instruments. During the epidemic, researchers applied the instruments to do blind clinical experiments. In early March, the Institute of Preventive Medicine was approved by the Central Epidemic Command Center as a quarantine institution to test severe infectious pneumonia. In May, it helped LabTurbo become the second manufacturer who obtained Taiwan TFDA Emergency Use Authorization (EUA) and approval from the Ministry of Health and Welfare to manufacture medical devices.

LabTurbo is an affiliated enterprise of Taigen Bioscience Corporation. According to results of many scientific journals, its fully automated nucleic extraction and gene detection system (AIO 48) can achieve high sensitivity in terms of coronavirus detection, several times higher than that of the same type of instruments of overseas companies. Besides, it has passed specimen blind tests of several world-class third party verification parties with the accuracy rate reaching 100% while the selling price is only one third to one half of products by major leading suppliers overseas. As a result, AIO 48 is widely used by medical institutions and hospitals, research institutions and government institutions.

As the only institute which has P4 high protection biosafety laboratory in Taiwan, Institute of Preventive Medicine of National Defense Medical Center was the first institute that used AIO 48 for epidemic prevention. Thanks to clinical evidence provided by the Institute of Preventive Medicine and Tri-Service General Hospital, products of LabTurbo successfully entered many hospitals and pathogen screening institutions to detect viruses and, ultimately, prevent the epidemic.

Under the condition of a continuing COVID-19 pandemic, there is still a large demand in detection instruments around the world, said Eric Dai. Since AIO 48 can handle large quantities of specimens at the same time with reduced need of manpower, simplified detection process, reduced variances caused by manual sample handling together with the advantages of fast screening resulting, small footprint and great ease-of-use, it is highly competitive. At present, LabTurbo exports 80% of the AIO 48 systems to the foreign countries, especially the United States, Philippines, Spain, Romania and Czech Republic. Facing next year’s market demand, LabTurbo will not only work actively to build the second supply chain but will also make tremendous efforts to intensify brand awareness.

As a pioneer in the epidemic prevention of Taiwan, yesterday (December 3, 2020) LabTurbo took part in the medical technology exhibition “Taiwan Healthcare+ Expo” at the Precision Detection Section at Nangang Exhibition Hall for the first time to show its products to the world and communicate with others. The exhibition is from December 3rd to December 6th, 2020. Eric Dai revealed that actually AIO is a multiple gene testing instrument which can detect numerous pathogens simultaneously. LabTurbo has already made positive cooperation with the Institution of Preventive Medicine to perform clinical testing with the effort to deploy ahead of time, aiming at any demand in epidemic prevention that may occur in the future.